CB-5083 | CAS#1542705-92-9, now 10g in stock.
USD 1650/G, assay more than 98%
Delivery soon.
Description: CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models . CB-5083 causes rapid and sustained accumulation of poly-ubiquitin in tumor xenografts after a single administration. CB-5083 showed activity to inhibit tumor growth in multiple rodent models of human cancer. Furthermore, CB-5083 appears to exhibit greater potency over current proteasome inhibitors that further validate targeting p97 and protein homeostasis in the treatment of cancer. (Last update: 1/4/2016).
USD 1650/G, assay more than 98%
Delivery soon.
2016 Shanghai CPHI, W5C47, Welcome!
EOS Med Chem, Medchem is
Big
執大象,天下往,往而無害,安平泰
辦公室: 0086-531-69905422-806(直通)
攜帶番號
& WhatsApp: +8618653174435
Skype: willgutian
Appearance:
Solid powder
Purity:
>98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility:
Soluble in DMSO, not in water
Shelf Life:
>2 years if stored properly
Drug Formulation:
This drug may be formulated in DMSO













![CAS # 1206524-85-7, MK-5172, (1aR,5S,8S,10R,22aR)-5-(1,1-Dimethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-methoxy-3,6-dioxo-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid](https://www.chemblink.com/structures/1206524-85-7.gif)

![CAS # 1350514-68-9, Grazoprevir, (1R,2S)-N-[[[(1R,2R)-2-[5-(3-Hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide cyclic (1→2)-ether, , MK 5172](https://www.chemblink.com/structures/1350514-68-9.gif)

